What does the evidence say about Pyrroloquinoline Quinone Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Pyrroloquinoline Quinone Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Introduction Oocyte maturation requires substantial ATP, and the resulting oxidative stress may impair follicular development. [Tsuji S (2026); evidence level 4] - Pyrroloquinoline quinone (PQQ), an antioxidant compound, protects mitochondria and promotes follicular development in animal models; however, its effects on human ovarian function remain unclear. [Tsuji S (2026); evidence level 4] - 1 2 3 Aging is characterized by a progressive decline in physiological and cognitive functions, which contributes to an increased risk of cognitive impairment and the development of neurodegenerative diseases, including dementia []. [Degens Tineke (2025); evidence level 4] - Growing evidence suggests that maintaining a healthy lifestyle, possibly through a healthy nutrient-rich diet, is crucial for reducing cognitive decline and for supporting cognitive performance in aging populations []. [Degens Tineke (2025); evidence level 4] - self-reported cognitive complaints, SCI, MCI, or (an increased risk for) dementia. [Degens Tineke (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.